DE60323876D1 - Verwendung von purinderivaten zur induktion der differenzierung überzähliger haarzellen und deiter-zellen im entwickelnden corti-organ zur behandlung von taubheit - Google Patents

Verwendung von purinderivaten zur induktion der differenzierung überzähliger haarzellen und deiter-zellen im entwickelnden corti-organ zur behandlung von taubheit

Info

Publication number
DE60323876D1
DE60323876D1 DE60323876T DE60323876T DE60323876D1 DE 60323876 D1 DE60323876 D1 DE 60323876D1 DE 60323876 T DE60323876 T DE 60323876T DE 60323876 T DE60323876 T DE 60323876T DE 60323876 D1 DE60323876 D1 DE 60323876D1
Authority
DE
Germany
Prior art keywords
cells
developing
differentiation
inducing
purine derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60323876T
Other languages
English (en)
Inventor
Laurent Meijer
Marie Knockaert
Brigitte Malgrange
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Original Assignee
Centre National de la Recherche Scientifique CNRS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS filed Critical Centre National de la Recherche Scientifique CNRS
Application granted granted Critical
Publication of DE60323876D1 publication Critical patent/DE60323876D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60323876T 2002-12-17 2003-12-17 Verwendung von purinderivaten zur induktion der differenzierung überzähliger haarzellen und deiter-zellen im entwickelnden corti-organ zur behandlung von taubheit Expired - Fee Related DE60323876D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43376702P 2002-12-17 2002-12-17
US43396002P 2002-12-18 2002-12-18
PCT/EP2003/015047 WO2004055154A2 (en) 2002-12-17 2003-12-17 Use of purine derivatives for inducing differentiation of supernumerary hair cells and deiters' cells in the developing organ of corti for treating deafness

Publications (1)

Publication Number Publication Date
DE60323876D1 true DE60323876D1 (de) 2008-11-13

Family

ID=32600163

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60323876T Expired - Fee Related DE60323876D1 (de) 2002-12-17 2003-12-17 Verwendung von purinderivaten zur induktion der differenzierung überzähliger haarzellen und deiter-zellen im entwickelnden corti-organ zur behandlung von taubheit

Country Status (6)

Country Link
US (1) US20060148829A1 (de)
EP (1) EP1585523B1 (de)
AT (1) ATE409484T1 (de)
AU (1) AU2003302747A1 (de)
DE (1) DE60323876D1 (de)
WO (1) WO2004055154A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2899107B1 (fr) * 2006-03-30 2008-06-13 Neurokin Entpr Unipersonnelle Utilisation de la (s)-roscovitine pour la fabrication d'un medicament
US9572815B2 (en) 2013-03-15 2017-02-21 St. Jude Children's Research Hospital Methods and compositions of p27KIP1 transcriptional modulators
CN108137595B (zh) * 2015-06-18 2021-04-20 听治疗有限责任公司 预防和治疗听力损失的方法和组合物
WO2022020114A2 (en) 2020-07-10 2022-01-27 Ting Therapeutics Llc Methods for the prevention and treatment of hearing loss

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2741881B1 (fr) * 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
CA2257839C (en) * 1996-07-12 2012-10-23 Genentech, Inc. Gamma-heregulin
DE19807426A1 (de) * 1998-02-23 1999-10-14 Otogene Biotechnologische Fors Verfahren zur Behandlung von Erkrankungen oder Störungen des Innenohrs
US6413974B1 (en) * 1998-02-26 2002-07-02 Aventis Pharmaceuticals Inc. 6,9,-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines
DE69912808T2 (de) * 1999-12-08 2004-09-30 Centre National De La Recherche Scientifique (C.N.R.S.) Verwendung von Hymenialdisin und dessen Derivaten zur Herstellung therapeutischer Mittel
US20020173507A1 (en) * 2000-08-15 2002-11-21 Vincent Santora Urea compounds and methods of uses
US20020151491A1 (en) * 2000-11-28 2002-10-17 Jian-Dong Li Composition and method for treating the over-production of mucin in diseases such as otitis media using an inhibitor of MUC5AC
MXPA04003758A (es) * 2001-10-22 2005-06-20 Univ New York State Res Found Inhibidores de proteina - cinasas y proteina-fosfatasas, metodos para disenarlos y metodos para usarlos.
US7005445B2 (en) * 2001-10-22 2006-02-28 The Research Foundation Of State University Of New York Protein kinase and phosphatase inhibitors and methods for designing them
US7700111B2 (en) * 2002-01-17 2010-04-20 The Regents Of The University Of Michigan Auditory nerve protection and re-growth

Also Published As

Publication number Publication date
AU2003302747A8 (en) 2004-07-09
US20060148829A1 (en) 2006-07-06
EP1585523A2 (de) 2005-10-19
ATE409484T1 (de) 2008-10-15
WO2004055154A2 (en) 2004-07-01
AU2003302747A1 (en) 2004-07-09
EP1585523B1 (de) 2008-10-01
WO2004055154A3 (en) 2004-11-04

Similar Documents

Publication Publication Date Title
AP2000001996A0 (en) Heterocyclic inhibitors of P38.
MY117696A (en) INHIBITORS OF p38
DE60037394D1 (de) VERWENDUNG VON p53 INHIBITOREN ZUR BEHANDLUNG VON NEBENERSCHEINUNGEN BEI DER KREBSTHERAPIE
ATE389649T1 (de) Substituierte amin-derivate und deren verwendung zur behandlung von angionese-bedingten erkrankungen
NO20014303L (no) JAK-3-inhibitorer for behandling av allergiske lidelser
YU49101A (sh) Karboksiaril supstituisani difenil karbamidi kao inhibitori raf kinaze
BR9811956B1 (pt) naftiridinonas e composição farmacêutica compreendendo as mesmas.
DE69718053D1 (de) in vitro methoden und verwendung von pharmazeutische zusammensetzungen für die BEHANDLUNG VON INNENOHRHAARZELLEN
AU8377698A (en) Inhibitors of p38
ATE350030T1 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
IS6585A (is) Hindrar fyrir mennskt fosfatidýl ínósítól-3-kínasa delta
ATE400577T1 (de) Anellierte dihydropyrane
RS20050070A (en) Use of 1kb kinase inhibitors for the treatment of pain
DE60008143D1 (de) Lipoxin-a4 und deren analoge zur behandlung von trockenen augen
ATE275400T1 (de) Verwendung von melatonin zur behandlung der androgenetischen und diffusen alopezie vom weiblichen typ
DE69911380D1 (de) Verwendung von isatin- und oxindolderivaten zur herstellung von arzeneimittel für die behandlung von mykobakteriellen erkrankungen
ATE330608T1 (de) Die verwendung von n-phenyl-2-pyrimidine-amine derivaten zur behandlung von entzündlichen erkrankungen
ATE359072T1 (de) Methode und zusammensetzung zur behandlung von resistenz gegen antihypertensiva und verwandten zuständen
ATE234617T1 (de) Verwendung des saredutant und seiner pharmazeutisch akzeptablen salze zur behandlung von schwere depression
DE60323876D1 (de) Verwendung von purinderivaten zur induktion der differenzierung überzähliger haarzellen und deiter-zellen im entwickelnden corti-organ zur behandlung von taubheit
MXPA02010759A (es) Derivados del acido (2-oxindol-3-ilidenil) acetico y su uso como inhibidores de la proteina quinasa.
DE69626816D1 (de) Verwendung von selegilin zur behandlung von gehörverlust bei säugetieren
BRPI0409475A (pt) inibição de vav na rejeição de enxerto
DE69920959D1 (de) Verwendung von riluzol zur behandlung von akustischen traumazuständen
TR199901385T2 (xx) Piperidin t�revleri.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee